Pimavanserin (Tradename: Nuplazid) is an antipsychotic in the atypical antipsychotic class used in the treatment of Parkinson's disease psychosis in the United States. It is not yet approved in Canada.
Unlike other antipsychotics, pimanvaserin is not a dopamine receptor antagonist. It is a highly selective serotonin 5-HT2A receptor antagonist.